142 related articles for article (PubMed ID: 20521869)
1. The safety of a novel sublingual rush induction phase for latex desensitization.
Nettis E; Di Leo E; Calogiuri G; Milani M; Delle Donne P; Ferrannini A; Vacca A
Curr Med Res Opin; 2010 Aug; 26(8):1855-9. PubMed ID: 20521869
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study.
Nettis E; Colanardi MC; Soccio AL; Marcandrea M; Pinto L; Ferrannini A; Tursi A; Vacca A
Br J Dermatol; 2007 Apr; 156(4):674-81. PubMed ID: 17493066
[TBL] [Abstract][Full Text] [Related]
3. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract.
Cisteró Bahima A; Sastre J; Enrique E; Fernández M; Alonso R; Quirce S; Gandarias B; Parmiani S; Rico P
J Investig Allergol Clin Immunol; 2004; 14(1):17-25. PubMed ID: 15160438
[TBL] [Abstract][Full Text] [Related]
4. Priming-like effect and successful desensitization after anaphylactic shock by latex sublingual immunotherapy.
Antico A; Pagani M; Crema A
Eur Ann Allergy Clin Immunol; 2007 Oct; 39(8):259-61. PubMed ID: 18237003
[TBL] [Abstract][Full Text] [Related]
5. Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study.
Bernardini R; Campodonico P; Burastero S; Azzari C; Novembre E; Pucci N; Massai C; De Martino M; Vierucci A
Curr Med Res Opin; 2006 Aug; 22(8):1515-22. PubMed ID: 16870076
[TBL] [Abstract][Full Text] [Related]
6. Latex sublingual immunotherapy: can its safety be predicted?
Buyukozturk S; Gelincik A; Ozşeker F; Colakoğlu B; Dal M
Ann Allergy Asthma Immunol; 2010 Apr; 104(4):339-42. PubMed ID: 20408345
[TBL] [Abstract][Full Text] [Related]
7. Component-resolved immunologic modifications, efficacy, and tolerance of latex sublingual immunotherapy in children.
Lasa Luaces EM; Tabar Purroy AI; García Figueroa BE; Anda Apiñaniz M; Sanz Laruga ML; Raulf-Heimsoth M; Barber Hernández D
Ann Allergy Asthma Immunol; 2012 May; 108(5):367-72. PubMed ID: 22541410
[TBL] [Abstract][Full Text] [Related]
8. Sublingual immunotherapy for latex allergy: tolerability and safety profile of rush build-up phase.
Nucera E; Schiavino D; Sabato V; Colagiovanni A; Pecora V; Rizzi A; Aruanno A; Milani M; Pollastrini E; Patriarca G
Curr Med Res Opin; 2008 Apr; 24(4):1147-54. PubMed ID: 18334054
[TBL] [Abstract][Full Text] [Related]
9. Natural rubber latex allergy in children: clinical and immunological effects of 3-years sublingual immunotherapy.
Bernardini R; Pecora S; Milani M; Burastero SE
Eur Ann Allergy Clin Immunol; 2008 Dec; 40(4):142-7. PubMed ID: 19227650
[TBL] [Abstract][Full Text] [Related]
10. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers.
Leynadier F; Herman D; Vervloet D; Andre C
J Allergy Clin Immunol; 2000 Sep; 106(3):585-90. PubMed ID: 10984382
[TBL] [Abstract][Full Text] [Related]
11. Anaphylaxis by latex sublingual immunotherapy.
Antico A; Pagani M; Crema A
Allergy; 2006 Oct; 61(10):1236-7. PubMed ID: 16942577
[No Abstract] [Full Text] [Related]
12. Sublingual desensitization in children with congenital malformations and latex allergy.
Nucera E; Schiavino D; Pollastrini E; Rendeli C; Pietrini D; Tabacco F; De Pasquale T; Ausili E; Sabato V; Roncallo C; Patriarca G
Pediatr Allergy Immunol; 2006 Dec; 17(8):606-12. PubMed ID: 17121589
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled clinical trial of sublingual immunotherapy in natural rubber latex allergic patients.
Gastaminza G; Algorta J; Uriel O; Audicana MT; Fernandez E; Sanz ML; Muñoz D
Trials; 2011 Aug; 12():191. PubMed ID: 21827704
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children.
Tripodi S; Di Rienzo Businco A; Benincori N; Scala G; Pingitore G
Int Arch Allergy Immunol; 2006; 139(2):149-52. PubMed ID: 16374025
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
16. Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study.
Alvarez-Cuesta E; Berges-Gimeno P; González-Mancebo E; Fernández-Caldas E; Cuesta-Herranz J; Casanovas M
Allergy; 2007 Jul; 62(7):810-7. PubMed ID: 17573730
[TBL] [Abstract][Full Text] [Related]
17. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study.
Sieber J; Neis M; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Merk H
Expert Opin Drug Saf; 2012 Jan; 11(1):7-13. PubMed ID: 21980934
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
Allergy; 2009 Jan; 64(1):179-86. PubMed ID: 19076534
[TBL] [Abstract][Full Text] [Related]
19. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract.
Enrique E; Pineda F; Malek T; Bartra J; Basagaña M; Tella R; Castelló JV; Alonso R; de Mateo JA; Cerdá-Trias T; San Miguel-Moncín Mdel M; Monzón S; García M; Palacios R; Cisteró-Bahíma A
J Allergy Clin Immunol; 2005 Nov; 116(5):1073-9. PubMed ID: 16275379
[TBL] [Abstract][Full Text] [Related]
20. [Treatment perspectives: immunotherapy with latex].
Tabar AI; Anda M; Gómez B; García B; Lizaso MT; Echechipía S; Arroabarren E; Olaguibel JM
Allergol Immunopathol (Madr); 2002; 30(3):163-70. PubMed ID: 11988148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
